ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer...
Read moreLatest News
Category: Clinical
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Telix announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s investigational renal cancer therapy at MSK in New...
Read more
ProstACT Update: TARGET Study Ethics Approval
Telix’s ProstACT TARGET Phase II clinical trial of prostate cancer antibody therapy candidate TLX591 has been granted Human Research Ethics Committee...
Read more
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
Telix announces that the FDA has granted Orphan Drug Designation for TLX66 (90Y-besilesomab), for conditioning treatment prior to hematopoietic stem cell transplant...
Read more
Telix Advances Development of Glioblastoma Therapy Program
Telix announces significant progress in advancing the Company’s glioblastoma therapy candidate TLX101 into the next stage of clinical...
Read more
EAU Updates Guidance for PSMA-PET Imaging
Telix welcomes the updated 2022 ‘Guidelines on Prostate Cancer’ (the Guidelines) from the European Association of Urology (EAU), which demonstrate an increasing recognition of the clinical utility of prostate specific membrane antigen...
Read more
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
Telix announces the ZIRCON Phase III study of investigational kidney cancer imaging agent, TLX250-CDx has dosed the target enrolment of 252...
Read more
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
Telix and Kanazawa University announce that the Phase I clinical study of TLX591-CDx for prostate cancer imaging in Japanese patients has met its...
Read more
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
Telix announces that the first patient has been dosed in the Company’s PSMA-targeting ‘ProstACT’ therapeutic...
Read more
Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study
Telix is pleased to announce a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or...
Read more